Identification of nafamostat mesylate as a selective stimulator of NK cell IFN-gamma production via metabolism-related compound library screening

Natural killer (NK) cells play important roles in controlling virus-infected and malignant cells. The identification of new molecules that can activate NK cells may effectively improve the antiviral and antitumour activities of these cells. In this study, by using a commercially available metabolism-related compound library, we initially screened the capacity of compounds to activate NK cells by determining the ratio of interferon-gamma (IFN-gamma)(+) NK cells by flow cytometry after the incubation of peripheral blood mononuclear cells (PBMCs) with IL-12 or IL-15 for 18 h. Our data showed that eight compounds (nafamostat mesylate (NM), loganin, fluvastatin sodium, atorvastatin calcium, lovastatin, simvastatin, rosuvastatin calcium, and pitavastatin calcium) and three compounds (NM, elesclomol, and simvastatin) increased the proportions of NK cells and CD3(+) T cells that expressed IFN-gamma among PBMCs cultured with IL-12 and IL-15, respectively. When incubated with enriched NK cells (purity >= 80.0%), only NM enhanced NK cell IFN-gamma production in the presence of IL-12 or IL-15. When incubated with purified NK cells (purity >= 99.0%), NM promoted NK cell IFN-gamma secretion in the presence or absence of IL-18. However, NM showed no effect on NK cell cytotoxicity. Collectively, our study identifies NM as a selective stimulator of IFN-gamma production by NK cells, providing a new strategy for the prevention and treatment of infection or cancer in select populations.

Automated summary

This study identified nafamostat mesylate (NM) as a selective stimulator of IFN-gamma production by NK cells, providing a new strategy for the prevention and treatment of infection or cancer in select populations.